FIRE Study: Real-World Effectiveness and Safety of Ibrutinib in Clinical Practice in Patients with CLL and MCL

por Dartigeas, Caroline, Slama, Borhane, Doyle, Margaret, Tapprich, Christoph, Albrecht, Claire, Dupuis, Sandrine, Wapenaar, Robert, Schmidt-Hieber, Charlotte, Leblond, Veronique
Publicado 2022

P109: One-Day Brentuximab-Bendamustine (120mg/m2) every 21 days is a feasible and safe treatment for relapsed/refractory Hodgkin lymphoma

por Moatti, Hannah, Laroque, Marie-Céleste, Renaud, Loïc., Ravdan, Odonchimeg, Schmidt-Hieber, Charlotte, Madelaine, Isabelle, Di Blasi, Roberta, Thieblemont, Catherine, Brice, Pauline
Publicado 2022